Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $3.6 million.

  • Catalyst Pharmaceuticals' Change in Account Payables fell 1976.61% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year decrease of 13542.0%. This contributed to the annual value of $1.8 million for FY2024, which is 8338.26% down from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Change in Account Payables of $3.6 million as of Q3 2025, which was down 1976.61% from -$5.7 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Change in Account Payables' 5-year high stood at $10.2 million during Q4 2023, with a 5-year trough of -$5.7 million in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Change in Account Payables value was $177000.0 (recorded in 2023), while the average stood at $254736.8.
  • Over the last 5 years, Catalyst Pharmaceuticals' Change in Account Payables had its largest YoY gain of 893750.0% in 2022, and its largest YoY loss of 87369.86% in 2022.
  • Catalyst Pharmaceuticals' Change in Account Payables (Quarter) stood at $16000.0 in 2021, then surged by 8937.5% to $1.4 million in 2022, then soared by 605.19% to $10.2 million in 2023, then tumbled by 50.67% to $5.0 million in 2024, then decreased by 29.07% to $3.6 million in 2025.
  • Its Change in Account Payables was $3.6 million in Q3 2025, compared to -$5.7 million in Q2 2025 and -$5.4 million in Q1 2025.